Target Application Areas
Predictive Biomarkers: Do cytokine signatures in blood correlate to likelihood of drug treatment response?
Tumor shrinkage markers: Can specific biomarkers (cytokines or other analytes) predict tumor shrinkage in advance of imaging?
Hot & Cold Tumor: Do certain immunological signatures correlate with hot tumor and cold tumor differentiation?
Cytokine Release Syndrome: Can early measurement of cytokine production post treatment correlate with Cytokine Release Syndrome?
Cytokine Release neurotoxicity: Severe CRS has been shown to correlate with neurotoxicity. Can Simoa markers of neurodegeneration and Simoa CorPlex be used for early identification of CRS and help providers minimize neurotoxicity?
CAR T-Cell Therapies: Return of T-Cells to the body initiates an immune response. Can cytokine measurement help manage dose optimization and minimize toxicity?
Early detection/liquid biopsies: Can the difference between baseline healthy and early stage cancer patients be identified in blood by measuring tumor-related biomarkers in blood with Simoa technology?
Extracellular vesicles: Can Simoa sensitivity be applied to measuring protein content of tumor-derived exosomes as biomarkers of tumor activity and signaling?
GRANT AWARD RULES
All proposals submitted will be reviewed and considered by a panel of reviewers including both Quanterix employees as well as an external judge. Quanterix reserves the right to make all final determination on grant awards. A total of up to $50,000 will be awarded in kind towards assay development and sample running in the Quanterix Accelerator.No funds will be awarded for costs outside of the Accelerator. All proposals must be submitted by June 30, 2019, and winning proposals will be notified by July 31, 2019.